Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

TNFRSF11A Protein (AA 29-213, C-Term)

TNFRSF11A Origin: Human Host: HEK-293 Cells Recombinant > 95 % , as determined by Coomassie stained SDS-PAGE. WB Active
Catalog No. ABIN2666569
  • Target See all TNFRSF11A Proteins
    TNFRSF11A (Tumor Necrosis Factor Receptor Superfamily, Member 11a, NFKB Activator (TNFRSF11A))
    Protein Type
    Recombinant
    Biological Activity
    Active
    Protein Characteristics
    AA 29-213, C-Term
    Origin
    • 15
    • 10
    • 3
    Human
    Source
    • 7
    • 6
    • 5
    • 4
    • 1
    • 1
    • 1
    • 1
    HEK-293 Cells
    Application
    Western Blotting (WB)
    Purity
    > 95 % , as determined by Coomassie stained SDS-PAGE.
    Sterility
    0.22 μm filtered
    Endotoxin Level

    Less than 0.01 ng per μg cytokine as determined by the LAL method.

    Top Product
    Discover our top product TNFRSF11A Protein
  • Application Notes
    Optimal working dilution should be determined by the investigator.
    Comment

    Biological activity: ED50 = 50 - 200 ng/mL, as determined by inhibition of osteoclast differentiation induced by RANKL (20 ng/mL) on RAW246.7 macrophages.

    Restrictions
    For Research Use only
  • Format
    Liquid
    Reconstitution
    For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20 °C to -70 °C. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.
    Buffer
    0.22 μm filtered protein solution is in PBS, pH 7.2.
    Handling Advice
    Avoid repeated freeze/thaw cycles.
    Storage
    -20 °C
    Storage Comment
    Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.
  • Target
    TNFRSF11A (Tumor Necrosis Factor Receptor Superfamily, Member 11a, NFKB Activator (TNFRSF11A))
    Alternative Name
    RANK (TNFRSF11A Products)
    Synonyms
    RANK Protein, RGD1563614 Protein, TNFRSF11A Protein, Ly109 Protein, ODFR Protein, OFE Protein, Rank Protein, TRANCE-R Protein, mRANK Protein, CD265 Protein, FEO Protein, LOH18CR1 Protein, OPTB7 Protein, OSTS Protein, PDB2 Protein, TRANCER Protein, TNF receptor superfamily member 11A Protein, TNF receptor superfamily member 11a Protein, tumor necrosis factor receptor superfamily, member 11a, NFKB activator Protein, Tnfrsf11a Protein, TNFRSF11A Protein
    Background
    RANK was initially cloned from dendritic cells. It is a type I membrane 66 kD protein that is expressed in monocytes, macrophages, dendritic cells, osteoclast precursors, and among other cells. RANK and its ligand (RANKL) play a key role in bone homeostasis, organogenesis, immune tolerance, and cancer. RANK and RANKL are members of the TNF family and are respectively designated as TNFRSF11A and TNFSF11. RANK, as well as other TNF receptor members, lacks intrinsic enzymatic activity. Its signal transduction is carried out by the recruitment of various adaptor proteins, including TNFR-associated factors (TRAFs), leading to the activation of JNK, ERK, p38, NFATc1, AKT, and NF-κB signaling pathways. In addition, INF-γ, IFN-β, and ITAM-activated costimulatory signals crosstalk with RANK signaling to regulate osteoclastogenesis in the opposite manner. While IFN-γ and IFN-β inhibit, ITAM stimulates this process. RANK and its ligand are associated to bone diseases such as postmenopausal osteoporosis and bone loss in inflammatory conditions. RANKL expressed on activated T-cells induces bone loss and joint destruction in rheumatoid arthritis. Also, RANK provides signals during medullary thymic epithelial cells (mTEC) development. mTECs contribute to the selection and survival of immunosuppressive Foxp3-positive regulatory T cells.
    Molecular Weight
    The 191 amino acid recombinant protein has a predicted molecular mass of approximately 47.8 kDa. The protein migrates at approximately 60 kDa in DTT-reduced conditions and at approximately 120 kDa in non-reduced conditions by SDS-PAGE. The predicted N-ter
    Pathways
    NF-kappaB Signaling
You are here:
Support